225 related articles for article (PubMed ID: 11135691)
1. [Expression of ras oncogene p21 product and proliferating cell nuclear antigen in liver cirrhosis and the correlation with liver cell dysplasia].
Feng Z; He R; Lu Z; Ling Y
Zhonghua Gan Zang Bing Za Zhi; 2000 Dec; 8(6):343-5. PubMed ID: 11135691
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of ras oncogene p21 product in liver cirrhosis and hepatocellular carcinoma.
Nonomura A; Ohta G; Hayashi M; Izumi R; Watanabe K; Takayanagi N; Mizukami Y; Matsubara F
Am J Gastroenterol; 1987 Jun; 82(6):512-8. PubMed ID: 3034055
[TBL] [Abstract][Full Text] [Related]
3. Expression of ras and c-myc oncoproteins and hepatitis B surface antigen in human liver disease.
Tiniakos D; Spandidos DA; Yiagnisis M; Tiniakos G
Hepatogastroenterology; 1993 Feb; 40(1):37-40. PubMed ID: 8462926
[TBL] [Abstract][Full Text] [Related]
4. Liver cell dysplasia in liver cirrhosis and hepatocellular carcinoma.
Szczepański W
Pol J Pathol; 1997; 48(3):147-57. PubMed ID: 9401407
[TBL] [Abstract][Full Text] [Related]
5. Proliferating cell nuclear antigen (PCNA) activity in hepatocellular carcinoma, benign peri-neoplastic and normal liver.
Mun KS; Cheah PL; Baharudin NB; Looi LM
Malays J Pathol; 2006 Dec; 28(2):73-7. PubMed ID: 18376794
[TBL] [Abstract][Full Text] [Related]
6. Expression of c-kit protooncogen in hepatitis B virus-induced chronic hepatitis, cirrhosis and hepatocellular carcinoma: has it a diagnostic role?
Kara B; Doran F; Kara IO; Akkiz H; Sandikci M
Int J Clin Pract; 2008 Aug; 62(8):1206-11. PubMed ID: 18284441
[TBL] [Abstract][Full Text] [Related]
7. [Expression of GST-pi and HBV infection in hepatocellular carcinoma].
Shen LJ; Zhang ZJ; Zhang HX; Yang WB; Huang R
Ai Zheng; 2002 Jan; 21(1):29-32. PubMed ID: 12500393
[TBL] [Abstract][Full Text] [Related]
8. Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma.
Koskinas J; Petraki K; Kavantzas N; Rapti I; Kountouras D; Hadziyannis S
J Viral Hepat; 2005 Nov; 12(6):635-41. PubMed ID: 16255765
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of HBV and HCV infection in hepatocellular carcinoma and chronic liver disease--an autopsy based study.
Vaiphei K; Pal NS; Arora SK
Indian J Pathol Microbiol; 2006 Jul; 49(3):357-61. PubMed ID: 17001884
[TBL] [Abstract][Full Text] [Related]
10. Expression of insulin-like growth factor II in chronic hepatitis B, liver cirrhosis, and hepatocellular carcinoma.
Seo JH; Park BC
Gan To Kagaku Ryoho; 1995 Aug; 22 Suppl 3():292-307. PubMed ID: 7661600
[TBL] [Abstract][Full Text] [Related]
11. Nucleolar hypertrophy correlates with hepatocellular carcinoma development in cirrhosis due to HBV infection.
Trerè D; Borzio M; Morabito A; Borzio F; Roncalli M; Derenzini M
Hepatology; 2003 Jan; 37(1):72-8. PubMed ID: 12500191
[TBL] [Abstract][Full Text] [Related]
12. Histological features of cirrhosis with hepatitis C virus for prediction of hepatocellular carcinoma development; a prospective study.
Makino Y; Shiraki K; Sugimoto K; Ito T; Yamanaka T; Fujikawa K; Takase K; Nakano T
Anticancer Res; 2000; 20(5C):3709-15. PubMed ID: 11268443
[TBL] [Abstract][Full Text] [Related]
13. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients.
Fattovich G; Pantalena M; Zagni I; Realdi G; Schalm SW; Christensen E;
Am J Gastroenterol; 2002 Nov; 97(11):2886-95. PubMed ID: 12425564
[TBL] [Abstract][Full Text] [Related]
14. Three types of liver cell dysplasia (LCD) in small cirrhotic nodules are distinguishable by karyometry and PCNA labelling, and their features resemble distinct grades of hepatocellular carcinoma.
Zhao M; Zhang NX; Du ZY; Laissue JA; Zimmermann A
Histol Histopathol; 1994 Jan; 9(1):73-83. PubMed ID: 7911690
[TBL] [Abstract][Full Text] [Related]
15. High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity.
Donato MF; Arosio E; Del Ninno E; Ronchi G; Lampertico P; Morabito A; Balestrieri MR; Colombo M
Hepatology; 2001 Sep; 34(3):523-8. PubMed ID: 11526538
[TBL] [Abstract][Full Text] [Related]
16. Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a case-control study of 213 hepatocellular carcinoma patients from India.
Kumar M; Kumar R; Hissar SS; Saraswat MK; Sharma BC; Sakhuja P; Sarin SK
J Gastroenterol Hepatol; 2007 Jul; 22(7):1104-11. PubMed ID: 17559381
[TBL] [Abstract][Full Text] [Related]
17. The expression of transforming growth factor-alpha in cirrhosis, dysplastic nodules, and hepatocellular carcinoma: an immunohistochemical study of 70 cases.
Yeh MM; Larson AM; Campbell JS; Fausto N; Rulyak SJ; Swanson PE
Am J Surg Pathol; 2007 May; 31(5):681-9. PubMed ID: 17460450
[TBL] [Abstract][Full Text] [Related]
18. GADD45-alpha expression in cirrhosis and hepatocellular carcinoma: relationship with DNA repair and proliferation.
Gramantieri L; Chieco P; Giovannini C; Lacchini M; Treré D; Grazi GL; Venturi A; Bolondi L
Hum Pathol; 2005 Nov; 36(11):1154-62. PubMed ID: 16260267
[TBL] [Abstract][Full Text] [Related]
19. P21/WAF1 is an independent survival prognostic factor for patients with hepatocellular carcinoma after resection.
Kao JT; Chuah SK; Huang CC; Chen CL; Wang CC; Hung CH; Chen CH; Wang JH; Lu SN; Lee CM; Changchien CS; Hu TH
Liver Int; 2007 Aug; 27(6):772-81. PubMed ID: 17617120
[TBL] [Abstract][Full Text] [Related]
20. [Expressions of h-TERT, c-myc, PCNA and cell apoptosis in liver carcinogenesis].
Fu XM; Yang QX; Shao CK; Feng ZY
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):821-3. PubMed ID: 16793609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
